Biomarkers for Alzheimer's Disease Diagnosis
- PMID: 28164766
- PMCID: PMC5684784
- DOI: 10.2174/1567205014666170203125942
Biomarkers for Alzheimer's Disease Diagnosis
Abstract
Objective: The dramatic increase in the population with dementia expected in the next decades is accompanied by the establishment of novel and innovated methods that will offer accurate and efficient detection of the disease in its early stages. While Alzheimer's disease is the most common cause of dementia, by the time it is typically diagnosed, substantial neuronal loss and neuropathological lesions can damage many brain regions. The aim of this study is to investigate the main risk factors that affect and increase Alzheimer's disease progression over time even in cases with no significant memory impairment present. Several potential markers are discussed such as oxidative stress, metal ions, vascular disorders, protein dysfunctions and alterations in the mitochondrial populations.
Conclusion: A multiparametric model of Alzheimer's biomarkers is presented according to the latest classification of the disease.
Keywords: Alzheimer's disease biomarkers; metal ions; mild cognitive impairment; mitochondrial dynamics; oxidative stress; protein dysfunctions; vascular disorders.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Figures
Similar articles
-
Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.Brain. 2015 May;138(Pt 5):1327-38. doi: 10.1093/brain/awv029. Epub 2015 Feb 17. Brain. 2015. PMID: 25693589 Free PMC article.
-
The ROSAS Cohort: A Prospective, Longitudinal Study of Biomarkers for Alzheimer's Disease. Strategy, Methods and Initial Results.J Prev Alzheimers Dis. 2017;4(3):183-193. doi: 10.14283/jpad.2017.8. J Prev Alzheimers Dis. 2017. PMID: 29182709
-
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Alzheimers Dement. 2018. PMID: 29653606 Free PMC article. Review.
-
The evaluation of thiol-disulfıte balance, ischemıa albumın modıfıcation and seruloplazmine as a new oxidatıve stress in mild cognitive impairment and early stage alzheimer's disease patients.J Clin Neurosci. 2020 May;75:188-194. doi: 10.1016/j.jocn.2019.12.026. Epub 2020 Mar 27. J Clin Neurosci. 2020. PMID: 32223973
-
Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome.Eur J Pharmacol. 2017 Dec 15;817:7-19. doi: 10.1016/j.ejphar.2017.10.004. Epub 2017 Oct 5. Eur J Pharmacol. 2017. PMID: 28987272 Review.
Cited by
-
Plasmonic Nanoparticles as Optical Sensing Probes for the Detection of Alzheimer's Disease.Sensors (Basel). 2021 Mar 16;21(6):2067. doi: 10.3390/s21062067. Sensors (Basel). 2021. PMID: 33809416 Free PMC article. Review.
-
The Association Between Folate and Alzheimer's Disease: A Systematic Review and Meta-Analysis.Front Neurosci. 2021 Apr 14;15:661198. doi: 10.3389/fnins.2021.661198. eCollection 2021. Front Neurosci. 2021. PMID: 33935641 Free PMC article.
-
P-tau231 as a Diagnostic Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.Ann Indian Acad Neurol. 2022 Sep-Oct;25(5):845-851. doi: 10.4103/aian.aian_77_22. Epub 2022 Oct 31. Ann Indian Acad Neurol. 2022. PMID: 36560987 Free PMC article.
-
Activation of the IL-17/TRAF6/NF-κB pathway is implicated in Aβ-induced neurotoxicity.BMC Neurosci. 2023 Feb 23;24(1):14. doi: 10.1186/s12868-023-00782-8. BMC Neurosci. 2023. PMID: 36823558 Free PMC article.
-
Action of the Purinergic and Cholinergic Anti-inflammatory Pathways on Oxidative Stress in Patients with Alzheimer's Disease in the Context of the COVID-19 Pandemic.Neuroscience. 2023 Feb 21;512:110-132. doi: 10.1016/j.neuroscience.2022.12.007. Epub 2022 Dec 13. Neuroscience. 2023. PMID: 36526078 Free PMC article. Review.
References
-
- Kukull W.A., Bowen J.D. Dementia epidemiology. Med. Clin. North Am. 2002;86:573–590. - PubMed
-
- DeKosky S.T., Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003;302:830–834. - PubMed
-
- Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., et al. Scheltens P research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical